Biotechnology Industry Organization Lauds Senate Passage Of Strengthened Two-Year R&D Credit, USA
Main Category: Pharma Industry / Biotech IndustryArticle Date: 03 Oct 2008 - 6:00 PDT
email to a friend 
printer friendly 
opinions
Urges House to Pass Economic Stabilization Package, to Bolster Investor Confidence and Hasten Therapeutic Development
The Biotechnology Industry Organization (BIO) today lauded U.S. Senate passage of a 2-year extension of the federal research and development (R&D) tax credit and urged the House to pass the package when it is considered on Friday. The R&D tax credit extension is part of the "Emergency Economic Stabilization Act of 2008."
"In today's precarious markets, biotechnology companies need the stabilizing influence that the R&D credit can provide," said Jim Greenwood, President and CEO of BIO. "Much of the promise of biotech therapies for auto-immune diseases, 'superbugs,' biofuels, and many other innovations depends on fostering innovative research through measures like the R&D credit."
"As we approach the end of the year," Greenwood continued, "These businesses face ever more uncertainty about their future, specifically their ability to plan for investments in R&D here in the U.S. It is essential that the House pass the economic stabilization legislation, including a 2-year extension of a strengthened R&D credit, before the 110th Congress adjourns."
Greenwood noted that the economic stabilization legislation includes an increase in the Alternative Simplified Credit (ASC) method rate, which would "strengthen and modernize the R&D credit, something that is long overdue. In a world of mobile capital and increasingly sophisticated and well-trained workforces abroad, the U.S. must employ every measure possible to keep the high-wage jobs associated with research and development here at home. A strengthened and longer-term R&D credit will help to accomplish this goal."
Click here to read BIO's letter to House leadership supporting passage of the "Emergency Economic Stabilization Act of 2008," and here to read a letter signed by a broad coalition of businesses, environmental organizations, public health advocates, electric utilities, agricultural organizations, investors, labor groups, nongovernmental organizations, states, and trade associations urging enactment of a tax extenders bill before Congress leaves for the election recess.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Biotechnology Industry Organization
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/124171.php>
APA
http://www.medicalnewstoday.com/releases/124171.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Cost And Value Of Biopharmaceuticals
posted by Dan on 3 Oct 2008 at 7:37 pmRecently, you may have heard or read in mass media sources about the issue of pharmacy benefit managers who have clients that are prescribed biologic medications. These patients are required to pay a great deal of money for such meds due to the placement of these types of medications on their PBMs.
This is due to the status on the PBM of biopharmaceutical medications, which is known as Tier 4 status, which requires patients to pay higher co-pays for these meds. Tier 4, which also includes lifestyle meds, is determined by the PBM based on variables such as rebates and discounts from the manufacturer, which are intended to be passed on to the PBM clients, and is as similar to PBMs requiring prior approval before reimbursement. However, in some cases, the PBMs fail to do this, and have been penalized for their self interest above patient interest as required when this activity is discovered. Regardless, because of the tier 4 status of biopharmaceuticals, very sick patients have to pay a great deal of money for these meds. PBMs, by the way, are pharmacy benefit managers created for the pharmaceutical needs of employees normally, and is a benefit along with their insurance through their employer. Typically, PBMs are an element of managed health care plans, yet determined by employers as far as what is paid through negotiations with PBMs, typically.
First of all, biopharmaceutical meds are specialty meds created differently than other typical meds, and therefore are have a unique molecular complexity that are designed for serious illnesses such as anemia or multiple sclerosis. Because of their uniqueness and exclusivity, they are very expensive- costing thousands a month for the payers. In addition, generics are not authorized to be produced as of yet for these types of meds. The cost of these biological meds is due more to the complex process of their creation, as the material costs are typically less expensive than traditional molecular medications, it is believed.
Biologic medications began to be used primarily in the 1980s and now presently make over 60 billion a year, with about 20 percent growth in this market annually. With anemia patients, oncology and dialysis clinics are targets for such meds in this category, as anemia is associated with their treatment and conditions for such diseases.
Yet, some claim that biopharmaceutical meds benefit patients to only a certain degree, as they do in fact extend the life of such patients, such as those on chemotherapy or dialysis, but by only a few months. So the high cost of these meds is questionable and has been analyzed by others, yet no substitutes exist for biopharmaceuticals, which is probably why the producers of these drugs can charge so much for these products. Efficacy of these biologic meds have also been questioned as well in other treatment aspects aside from life extension.
Then there is the issue of fraud with kickbacks and overuse of some of the biopharmaceutical meds used to treat anemia in dialysis clinics in particular. On a few occasions, doctors and clinics have been penalized for overusing the meds and for kickbacks in the form of discounts of the manufacturers. Ironically, the dialysis process was never patented, yet the many centers that exist have proven to be very profitable, more for some than others. An example is the situations where dialysis doctors, called nephrologists, have been accused of over-dosing patients with biologic meds to increase their income through their discount arrangement through the manufacturer of such meds, such as those biologics for anemia, and this arrangement is being investigated by regulators and encouraged by the representatives of such meds.
Presently, there are many that approach the FDA to aggressively insist that generic biologics be allowed into the market for the benefit of these critically ill patients, and this would be of great benefit for such patients, and this can be done, as far as the generic creation of these types of medications. And their efforts have been somewhat successful, as generic equivalents of biopharmaceuticals, called biosimilars, could be manufactured and available within the next few years. However, this situation of delays illustrates one of many flaws in the U.S. Health Care System- when the sickest have to complicate their illnesses by possible financial stress, such as the case with biologic meds. Relief is needed, and should be demanded by the public. After all, why be so sick, and then be financially burdened? One solution or suggestion is to either lower the cost of these types of drugs, or allow generic forms to enter the market faster than what the situation is presently.
“A little learning is a dangerous thing.” ---- Alexander Pope
Dan Abshear
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
